Defence Therapeutics (XCNQ:DTC) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Days Payable?

Defence Therapeutics's average Accounts Payable for the three months ended in Dec. 2023 was C$0.00 Mil. Defence Therapeutics's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.00 Mil.

The historical rank and industry rank for Defence Therapeutics's Days Payable or its related term are showing as below:

XCNQ:DTC's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 150.695
* Ranked among companies with meaningful Days Payable only.

Defence Therapeutics's Days Payable stayed the same from Sep. 2022 (0.00) to Dec. 2023 (0.00). stayed the same

Defence Therapeutics Days Payable Historical Data

The historical data trend for Defence Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Days Payable Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Days Payable

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Days Payable	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Defence Therapeutics's Days Payable

For the Biotechnology subindustry, Defence Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Defence Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Defence Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Defence Therapeutics's Days Payable falls into.

Defence Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Defence Therapeutics's Days Payable for the fiscal year that ended in Jun. 2022 is calculated as

	Days Payable (A: Jun. 2022 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2021 )	+	Accounts Payable (A: Jun. 2022 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2022 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365
=	0					/	0	*	365
=	N/A

Defence Therapeutics's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Sep. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	0	*	365 / 4
=	0					/	0	*	365 / 4
=	N/A

Defence Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Executives

Sarkis Meterissian

Director